Download Rabbit anti-FHIT - Thermo Fisher Scientific

Qty: 100 µg/400 µl
Rabbit anti-FHIT
Catalog No. 71-9000
Lot No. See product label
Rabbit anti-FHIT
FORM
This polyclonal antibody is supplied as a 400 µl aliquot at 0.25 mg/mL in phosphate buffer saline (PBS), pH 7.4 containing
0.1% sodium azide (NaN3). The antibody is epitope affinity-purified from rabbit antiserum.
POLYCLONAL ANTIBODY DESIGNATION (PAD): ZR44
IMMUNOGEN
Full length human FHIT fusion protein with GST (glutathione amino transferase)
SPECIFICITY
This antibody detects full length (~17 kDA) FHIT protein in cell and tissue lysates derived from human and rat. It is not
reactive with mouse FHIT protein. Reactivity has been confirmed by Western blotting using lysates from rat brain, colon,
spleen, stomach, kidney, lung, small intestine and testes as well as 293T cells and COS cells transfected with a pCMV-FHITFLAG construct.
REACTIVITY
This antibody reacts with human and rat FHIT. Reactivity with other species has not been tested.
USAGE
The dilutions listed below are good starting points, however, optimal dilutions should be determined by the investigator for
each application.
ELISA: 0.1-1.0 µg/ml
Western Blotting: 0.3-1.0 µg/ml
Immunohistochemistry*: 0.5-3.0 µg/ml
* Formalin-fixed, paraffin embedded sections require a Heat Induced
Epitope Retrieval step (HIER).
STORAGE
Store at 2-8°C for up to one month. Store at -20°C for long term storage. Avoid repeated freezing and thawing.
BACKGROUND
Alterations and deletions within the FHIT (Fragile Histidine Triad) gene and concomitant perturbations of FHIT gene
expression are strongly linked to the genesis and establishment of human tumors of the lung,(1-3) cervix,(4,5) breast,(6,7)
(8)
(9)
(10)
stomach, pancreas, and other tissues. Originally identified by collaborating researchers in the U.S. and Japan , the
(11)
>500 kbp FHIT gene was shown to span the fragile chromosomal site FRA3b at band 3p14.2. These researchers and
subsequent others demonstrated that loss of heterozygousity or homozygous deletion at this locus are characteristics of
multiple tumor-derived cell lines including those from colon, stomach, and breast. Further evidence that FHIT acts as a tumor
suppressor in normal cells comes from experiments showing that tumorigenesis of cancer cells is inhibited by replacement of
(12)
the FHIT gene . The involvement of other genes within the FRA3B region in tumor suppression has also been
suggested.(6) In a comparative study of lung cancers from heavy smokers and non-smokers, alterations in the FHIT gene
(2)
were found at much higher rates (80% vs. 22%) in tumors from heavy smokers . Thus, FHIT may be a ready target for
carcinogens present in cigarette smoke.
(cont’d)
www.invitrogen.com
Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [email protected]
PI719000
(Rev 10/08) DCC-08-1089
Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website,
www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these
products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
(71-9000 cont’d)
REFERENCES
1.
Sozzi, G. et al. Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res. 57:5207-5212
(1997).
2. Sozzi, G. et al. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res. 57:2121-2123 (1997).
3. Sozzi, G. et al. The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 85:17-26 (1996).
4. Greenspan, D.L. et al; Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res. 57:4692-4698 (1997).
5. Wistuba, I.I. et al. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer
Res. 57:3154-3158 (1997).
6. Ahmadian, M. et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast
cancer probands. Cancer Res. 57:3664-3668 (1997).
7. Man, S. et al. High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive
breast cancers. Cancer Res. 56:5484-5489 (1996).
8. Gemma, A. et al. FHIT mutations in human primary gastric cancer. Cancer Res. 57:1435-1437 (1997).
9. Shridhar, R. et al. Frequent breakpoints in the 3p14.2 fragile site, FRA3B, in pancreatic tumors. Cancer Res. 56:4347-4350 (1996).
10. Ohta, M. et al. Cell 84:587-597 (1996).
11. Inoue, H. et al. PNAS 96:14584-14589 (1997)
12. Siphrashvilli, P. et al. PNAS 94:13771-13776 (1997).
RELATED PRODUCTS
Product
Polyclonal Rabbit anti-FHIT
Polyclonal Rabbit anti-FHIT
Product
Goat anti-Rabbit IgG (H+L)
(ZyMAX™ Grade)
Clone/PAD
ZR44
ZP54
Conjugate
Purified
FITC
TRITC
Cy™3
Cy™5
HRP
AP
Biotin
Cat. No.
18-0219
71-9100
Cat. No.
81-6100
81-6111
81-6114
81-6115
81-6116
81-6120
81-6122
81-6140
rec-Protein G
Protein A
Sepharose 4B
®
Sepharose 4B
®
10-1241
10-1041
Zymed® and ZyMAX™ are trademarks of Zymed Laboratories Inc. Cy™ is a trademark of Amersham Life Sciences, Inc.
®
Sepharose is a registered trademark of Pharmacia LKB.
For Research Use Only
SS000726
www.invitrogen.com
Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [email protected]
PI719000
(Rev 10/08) DCC-08-1089
Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website,
www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these
products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.